Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from EXAS

Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

Investors Business Daily

1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA Win

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Barchart

Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth

Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Cathie Wood Stock with 65% Upside Potential

This stock holds a spot in maverick investor Wood's flagship fund, and analysts agree the cutting-edge diagnostics specialist has plenty of growth potential from current levels.

Barchart

3 Cathie Wood Stocks Beating the Nasdaq This Year

The maverick fund manager catches a lot of heat for her stock picks, but these three ARKK standouts are absolutely crushing the broader Nasdaq Composite so far in 2023.

Barchart

Dow Jones Futures Fall On U.S. Debt Downgrade; AMD, ELF Lead 7 Earnings Movers

Futures fell as Fitch downgraded the U.S. debt rating. AMD and ELF Beauty were big earnings movers late

Investors Business Daily

Exact Sciences, A Cathie Wood Darling, Skids Despite A Sixth Big Quarter

Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The Wild Ride That Has Sent Exact Sciences 216% Higher Since October

Exact Sciences said the company's next-generation Cologuard outperformed the original test. EXAS stock seesawed on the news.

Investors Business Daily

Why Top 2% Stock Exact Sciences Is On An Eight-Month Hot Streak — And Just Hit A Profit-Taking Zone

The market for colon cancer screening is massive — and underserved. And that might be why EXAS stock is on an eight-month hot streak.

Investors Business Daily

Dow Jones Futures Fall Ahead Of Inflation Report; Airbnb Plunges On Guidance

The market rally fell near 2023 highs with a key inflation report due. Airbnb and Celsius were big earnings movers late.

Investors Business Daily

Exact Sciences, Guardant Health Put Up Big Sales Beats As They Target The 'Most Preventable' Cancer

Exact Sciences delivered a first-quarter report that "checked all the boxes," an analyst said as EXAS stock surged.

Investors Business Daily

Exact Sciences, A Top 5% Stock, Beat Quarterly Expectations

Exact Sciences delivered a second consecutive quarter of sales growth acceleration and EXAS stock rose on Wednesday.

Investors Business Daily

Exact Sciences Raises Fourth-Quarter Estimates Above Expectations

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fourth quarter.

Investors Business Daily

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences massively beat third-quarter expectations and raised its full-year outlook — and EXAS stock skyrocketed on Friday.

Benzinga

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%. Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

StockNews.com

5 Cathie Wood Stocks Wall Street Predicts Will Rally 76% to 99%

Renowned institutional investor Cathie Wood of Ark Investments fame is known for her market-beating investment strategies. Ark’s portfolio companies are attractive investments due to their long-term high growth potential and ability to withstand the current industry headwinds. Thus, Wall Street analysts expect fundamentally solid Cathie Wood stocks Coinbase (COIN), Zoom…

Benzinga

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increas

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.